Literature DB >> 2875590

Non-pituitary actions of somatostatin. A review on the therapeutic role of SMS 201-995 (sandostatin).

S W Lamberts.   

Abstract

Natural Somatostatin has a short half-life (3 min), is only active after intravenous administration and causes a rebound hypersecretion of hormones after discontinuation of administration. Recently a long-acting powerful Somatostatin analog was developed (SMS 201-995; Sandostatin) which has a half-life of 113 min after subcutaneous administration. After administration of this analog no rebound hypersecretion of hormones was observed. In the present review the effects of the acute administration and of long-term treatment with SMS 201-995 in acromegalic patients is discussed. In addition the potential role of therapy with Somatostatin analogs and the preliminary effects of Somatostatin and/or SMS 201-995 are discussed in disorders of gastro-intestinal function (haemorrhages, diarrhoea, pancreatitis and endocrine pancreatic tumours), diabetes mellitus, central nervous system disturbances and oncology. Finally, several aspects of the tolerance, tachyphylaxis and side effects of SMS 201-995 are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2875590     DOI: 10.1530/acta.0.111s0041

Source DB:  PubMed          Journal:  Acta Endocrinol Suppl (Copenh)        ISSN: 0300-9750


  2 in total

Review 1.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Decreased insulin requirements after LAR-octreotide but not after lanreotide in an acromegalic patient.

Authors:  S M Webb; E Ortega; J Rodríguez-Espinosa; M E Mato; R Corcoy
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.